



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: JILL GILES KOMAR ET AL

Serial No.: 10/720,323

Art Unit:

Filed

: NOVEMBER 24, 2003

Examiner:

For

: ANTI-DUAL INTEGRIN

ANTIBODIES,

COMPOSITIONS,

Docket No. CEN 249CIPNP

METHODS AND USES.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

FEBRUARY 10, 2005
(Date of Deposit)

KENNETH J. DOW (Name of applicant, assignee, or Registered Representative)

•

FEBRUARY 10, 2005

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with \square the
first or _second After Final Submission, therefore:
Statement in Accordance with §1.97(e)
(attached); or
☐ Please charge Deposit Account No. 10-
0750/CEN249CIPNP/KD the fee of $$180.00$ as set
forth in §1.17(p).
☐ In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:

Statement in Accordance with §1.97(e)
(attached); or Please charge Deposit Account No. 10- 0750/CEN249CIPNP/KD the fee of \$180.00 as set
forth in §1.17(p).
In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).
☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.☐ Copies of references listed on the attached Form PTO
1449 are enclosed herewith EXCEPT THAT:
In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not

enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).

 \boxtimes There are no listed references which are not in the English language.

The relevance of those listed references which are not in the English language is as follows:

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

 \boxtimes Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CEN249CIPNP/KD. This form is submitted in triplicate.

Respectfully submitted,

KENNETH J. DOW

Reg. No. 32,890

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (610) 651-7422 DATED: FEBRUARY 10, 2005



Page 1 of 1

Application Number	10/720,323
Filing Date	NOVEMBER 24,
	2003
First Named Inventor	JILL GILES-KOMAR
Group Art Unit	
Examiner Name	
Attomey Docket Number	CEN249CIPNP

U.S. PATENT DOCUMENTS

	Cite No. ¹	Name of Patentee or Applicant of Cited Document	U.S. Patent Docu	··		
Examiner Initials			Number	Kind Code ² (if known)	Pages, Columns, Lines, where relevant passages or relevant figures appear	
		 				
			<u> </u>			
			-			
			ATENT DOCUME			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document	Foreign Pa	atent Docume Number ⁴ I	nt KindCode ⁵	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
					_		
					-		
					+		
		OTHER PRIOR ART - N	ON BATEN	LITEDATUR	E DOCUMEN	TC.	
	I	Include name of the author (in C					
Examiner	Cite						T²
's Initials*	No.¹		title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				
		MITJANS et al, "In Vivo Therapy of Malignant Melanoma by Means of Antagonists of αν Integrins," Int. J. Cancer, 2000, pp 716-723, Vol. 87, Wiley-Liss, Inc., Spain.					
	MITJANS et al, "An anti-αv-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice," Journal of Cell Science, 1995, pp 2825-2838, Vol. 108, The Company of Biologists Limited, Great Britain.						
	CASEL et al, "RGD Peptides and Moncolonal Antibodies, Antagonists of α _ν -Integrin, Enter the Cells by Independent Endocytic Pathways," Laboratory Investigation, 2001, pp 1615-1626, Vol. 81, No. 12, The United States and Canadian Academy of Pathology, Inc., USA.						
					·		

Examiner	Date		
Signature	Considered		